secwatch.observer — SEC 8-K summary
======================================

Issuer:     Compass Therapeutics, Inc. (CMPX)
CIK:        0001738021
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001171843-24-004669
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Compass Therapeutics Q2 net loss $13.1M; CTX-009 BTC trial enrollment completed, top-line data Q1 2025
--------------------------------------------------------------------------------

- Net loss of $13.1M ($0.10 per share) for Q2 2024 vs $11.3M loss in Q2 2023.
- Cash and marketable securities $146M as of June 30, 2024; cash runway into Q1 2027.
- Completed enrollment (n=150) in COMPANION-002 Phase 2/3 trial of CTX-009 in BTC; top-line data expected Q1 2025.
- Stage 1 of COMPANION-003 in CRC showed ORR 5%, median PFS 3.9 months, median OS 10.2 months; designing second-line DLL4+ study.
- Discontinuing CTX-471 + KEYTRUDA combo due to cytokine suppression; planning Phase 2 monotherapy with new biomarker.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324004669/0001171843-24-004669-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1738021/000117184324004669/f8k_081024.htm
  HTML page:      https://secwatch.observer/filing/0001171843-24-004669

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer